Bioxyne Ltd (BXN) - Total Assets
Based on the latest financial reports, Bioxyne Ltd (BXN) holds total assets worth AU$34.63 Million AUD (≈ $24.50 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bioxyne Ltd - Total Assets Trend (2000–2025)
This chart illustrates how Bioxyne Ltd's total assets have evolved over time, based on quarterly financial data. Also see market value of Bioxyne Ltd for the company's overall valuation and market capitalisation.
Bioxyne Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Bioxyne Ltd's total assets of AU$34.63 Million consist of 82.0% current assets and 18.0% non-current assets. Review Bioxyne Ltd balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 36.7% |
| Accounts Receivable | AU$2.35 Million | 11.3% |
| Inventory | AU$4.09 Million | 19.6% |
| Property, Plant & Equipment | AU$3.37 Million | 16.1% |
| Intangible Assets | AU$385.64K | 1.8% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Bioxyne Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Bioxyne Ltd stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioxyne Ltd's current assets represent 82.0% of total assets in 2025, a decrease from 99.7% in 2000.
- Cash Position: Cash and equivalents constituted 36.7% of total assets in 2025, down from 99.6% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is inventory at 19.6% of total assets.
Bioxyne Ltd Competitors by Total Assets
Key competitors of Bioxyne Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Nestle S.A.
SW:NESN
|
Switzerland | CHF128.38 Billion |
|
Henan Shuanghui Investment & Development Co Ltd
SHE:000895
|
China | CN¥40.87 Billion |
|
Unibel S.A
PA:UNBL
|
France | €4.09 Billion |
|
The a2 Milk Company Ltd
AU:A2M
|
Australia | AU$1.96 Billion |
|
Guangdong Haid Group Co Ltd
SHE:002311
|
China | CN¥55.29 Billion |
|
JiangXi Tianxin Pharm Co Ltd
SHG:603235
|
China | CN¥6.25 Billion |
|
Herbalife Nutrition Ltd
NYSE:HLF
|
USA | $2.79 Billion |
|
Beingmate Baby & Child Food Co Ltd
SHE:002570
|
China | CN¥3.70 Billion |
Bioxyne Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.79 | 1.73 | 3.96 |
| Quick Ratio | 1.65 | 1.18 | 3.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$18.39 Million | AU$4.91 Million | AU$1.97 Million |
Bioxyne Ltd - Advanced Valuation Insights
This section examines the relationship between Bioxyne Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.11 |
| Latest Market Cap to Assets Ratio | 5.79 |
| Asset Growth Rate (YoY) | 212.1% |
| Total Assets | AU$20.90 Million |
| Market Capitalization | $120.96 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Bioxyne Ltd's assets at a significant premium (5.79x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Bioxyne Ltd's assets grew by 212.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bioxyne Ltd (2000–2025)
The table below shows the annual total assets of Bioxyne Ltd from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$20.90 Million ≈ $14.79 Million |
+212.08% |
| 2024-06-30 | AU$6.70 Million ≈ $4.74 Million |
-62.15% |
| 2023-06-30 | AU$17.69 Million ≈ $12.52 Million |
+3870.75% |
| 2022-06-30 | AU$445.59K ≈ $315.28K |
-83.36% |
| 2021-06-30 | AU$2.68 Million ≈ $1.90 Million |
-19.69% |
| 2020-06-30 | AU$3.34 Million ≈ $2.36 Million |
-16.02% |
| 2019-06-30 | AU$3.97 Million ≈ $2.81 Million |
-21.36% |
| 2018-06-30 | AU$5.05 Million ≈ $3.57 Million |
+6.54% |
| 2017-06-30 | AU$4.74 Million ≈ $3.35 Million |
+135.88% |
| 2016-06-30 | AU$2.01 Million ≈ $1.42 Million |
+32.82% |
| 2015-06-30 | AU$1.51 Million ≈ $1.07 Million |
+0.92% |
| 2014-06-30 | AU$1.50 Million ≈ $1.06 Million |
+113.49% |
| 2013-06-30 | AU$702.22K ≈ $496.87K |
-89.84% |
| 2012-06-30 | AU$6.91 Million ≈ $4.89 Million |
+3030.52% |
| 2011-06-30 | AU$220.73K ≈ $156.18K |
-26.07% |
| 2010-06-30 | AU$298.58K ≈ $211.27K |
-38.52% |
| 2009-06-30 | AU$485.63K ≈ $343.61K |
+0.67% |
| 2008-06-30 | AU$482.42K ≈ $341.34K |
-20.93% |
| 2007-06-30 | AU$610.13K ≈ $431.71K |
-43.15% |
| 2006-06-30 | AU$1.07 Million ≈ $759.44K |
-17.51% |
| 2005-06-30 | AU$1.30 Million ≈ $920.67K |
-45.30% |
| 2004-06-30 | AU$2.38 Million ≈ $1.68 Million |
+20.11% |
| 2003-06-30 | AU$1.98 Million ≈ $1.40 Million |
-59.56% |
| 2002-06-30 | AU$4.90 Million ≈ $3.47 Million |
-48.79% |
| 2001-06-30 | AU$9.56 Million ≈ $6.77 Million |
-23.75% |
| 2000-06-30 | AU$12.54 Million ≈ $8.87 Million |
-- |
About Bioxyne Ltd
Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply of Novel Medicines, Cannabis, Psilocybin, and MDMA; Manufacture and Distribution (Wholesale, Onlin… Read more